CRNX
Crinetics Pharmaceuticals, Inc.
Latest Form 4:Sale$120KbyVivaldi Coelho Rogerio (Director) · filed Jul 7, 2026
Crinetics Pharmaceuticals, Inc. (CRNX) has 44 SEC Form 4 filings (97 transaction rows) in the rolling window, disclosed by 9 distinct insiders. Most recent filing: Sep 1, 2026.
Inside the rolling window, 9 insiders at Crinetics Pharmaceuticals, Inc. reported no open-market purchases and 16 open-market sales totaling $7.8M. The most active filer is Chief Med and Dev Officer Pizzuti Dana with 4 filings. Insiders have net sold $5.6M over the trailing 6 months. The most recent open-market filing is a sale of 3,000 shares by Director Vivaldi Coelho Rogerio, dated Jul 2, 2026, worth $120K.
- Industry:Biotechnology
- CEO:R. Scott Struthers
- Employees:594
- HQ:San Diego, CA, US
- IPO:2018-07-18
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$7.8M
reported sales (SEC code S)
Unique Insiders
9
in the rolling window
Market Cap
$9.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
Vivaldi Coelho RogerioFirst in 4 months | Director | Sale | 3,000 | $120K | Jul 7 | SEC ↗ |
Okey StephanieFirst in 3 months | Director | Sale | 6,900 | $246K | Jun 18 | SEC ↗ |
| Chief Dev. & Operating Officer | Sale | 85,163 | $3.4M | Apr 10 | SEC ↗ | |
Struthers Richard ScottFirst in 6 months | President & CEO | Sale | 21,981 | $822K | Mar 18 | SEC ↗ |
Knight Jeff E.First filing | Chief Operating Officer | Sale | 9,911 | $370K | Mar 18 | SEC ↗ |
Betz Stephen F.First filing | Chief Scientific Officer | Sale | 10,612 | $397K | Mar 18 | SEC ↗ |
Vivaldi Coelho RogerioFirst filing | Director | Sale | 5,000 | $181K | Mar 13 | SEC ↗ |
Okey StephanieFirst filing | Director | Sale | 3,000 | $119K | Mar 4 | SEC ↗ |
Schilke TobinFirst filing | Chief Financial Officer | Sale | 6,713 | $266K | Mar 4 | SEC ↗ |
Kalofonos IsabelFirst filing | Chief Commercial Officer | Sale | 2,500 | $138K | Jan 7 | SEC ↗ |
| Chief Med and Dev Officer | Sale | 5,000 | $225K | Dec 3 | SEC ↗ | |
| Chief Med and Dev Officer | Sale | 5,000 | $213K | Nov 5 | SEC ↗ | |
| Chief Med and Dev Officer | Sale | 5,000 | $209K | Oct 3 | SEC ↗ | |
Fust Matthew KFirst filing | Director | Sale | 16,000 | $716K | Sep 30 | SEC ↗ |
Struthers Richard ScottFirst filing | President & CEO | Sale | 4,000 | $180K | Sep 30 | SEC ↗ |
Pizzuti DanaFirst filing | Chief Med and Dev Officer | Sale | 5,000 | $161K | Sep 4 | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does CRNX have?
Crinetics Pharmaceuticals, Inc. (CRNX) has 44 SEC Form 4 filings (97 transaction rows) in the rolling 365-day window, disclosed by 9 distinct insiders. Most recent filing: Sep 1, 2026.
When was the most recent SEC Form 4 filing for CRNX?
The most recent Form 4 filing for CRNX on Tracefour is dated Sep 1, 2026.
Who is the most active insider at CRNX?
The most active SEC Form 4 filer at CRNX in the rolling window is Chief Med and Dev Officer Pizzuti Dana, with 4 filings.
What is the net insider flow at CRNX over the last 6 months?
Over the trailing 180 days, insiders at CRNX have net sold $5.6M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at CRNX in the current window?
Inside the rolling window, insiders at CRNX bought $0 and sold $7.8M based on SEC Form 4 filings.
Can I get alerts for CRNX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Crinetics Pharmaceuticals, Inc. (CRNX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Crinetics Pharmaceuticals, Inc. is in the Healthcare sector.